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The study of ﬂaviviruses, which cause some of the most important emerging tropical and sub-tropical
human arbovirus diseases, has greatly beneﬁted from the use of reverse genetic systems since its ﬁrst
development for yellow fever virus in 1989. Reverse genetics technology has completely revolutionized
the study of these viruses, making it possible to manipulate their genomes and evaluate the direct effects
of these changes on their biology and pathogenesis. The most commonly used reverse genetics system is
the infectious clone technology. Whilst ﬂavivirus infectious clones provide a powerful tool, their con-
struction as full-length cDNA molecules in bacterial vectors can be problematic, laborious and time con-
suming, because they are often unstable, contain unwanted induced substitutions and may be toxic for
bacteria due to viral protein expression. The incredible technological advances that have been made dur-
ing the past 30 years, such as the use of PCR or new sequencing methods, have allowed the development
of new approaches to improve preexisting systems or elaborate new strategies that overcome these prob-
lems. This review summarizes the evolution and major technical breakthroughs in the development of
ﬂavivirus reverse genetics technologies and their application to the further understanding and control
of these viruses and their diseases.
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According to the IXth Report of the International Committee on
Taxonomy of Viruses (King et al., 2011), the genus Flavivirus (fam-
ily Flaviviridae) contains 53 species of which 40 are known to cause
human disease including dengue virus (DENV), yellow fever virus
(YFV), Japanese encephalitis virus (JEV), West Nile virus (WNV)
and tick-borne encephalitis virus (TBEV). These viruses cause mil-
lions of human infections each year ranging from mild febrile
symptoms to fatal hemorrhagic/neurologic disease (Gubler, 2002;
Guzman et al., 2010; Halstead and Thomas, 2010; Hayes et al.,
2005; Monath, 2008). During recent decades, the dramatic increase
in the movement of humans, animals and commodities via modern
transportation, unplanned urbanization in tropical developing
countries and the lack of adequate public health infrastructures
have enabled these pathogens to expand their geographic ranges
to cause major epidemics (Artsob et al., 2009; Duffy et al., 2009;
Gould and Solomon, 2008; Gubler, 2004).
Flaviviruses are small (50 nm), enveloped, single-strand posi-
tive-sense RNA viruses. Their genomes vary between 10.5 and
11 kb and contain a single open reading frame (ORF) ﬂanked by
50 and 30 untranslated regions (UTRs) of approximately 100 nucle-
otides and 500 nucleotides respectively that form speciﬁc second-
ary structures required for genome replication and protein
translation (Gritsun and Gould, 2007; Lindenbach et al., 2007;
Strauss and Strauss, 1988). Translation of the ORF leads to synthe-
sis of a polyprotein that is cleaved by host and viral proteases to
release structural and non-structural viral proteins (Harris et al.,
2006). The structural proteins (C, prM, and E) are located in the
N-terminal portion of the polyprotein and the non-structural pro-
teins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) in the remain-
ing C-terminal portion of the polyprotein (Lindenbach et al., 2007).
The 50 end of the genome possesses a type I cap (m7GpppAmp)
and the 30 end of the genome lacks a 30 polyadenylate tail (Dong
et al., 2012). The ﬂaviviruses also contain a unique, subgenomic,
small (0.3–0.5 kb) non-coding RNA present in the 30 UTR of the
viral RNA, which is thought to be essential for virus replication in
cells and to modulate pathogenicity in animals (Pijlman et al.,
2008; Roby et al., 2014). More recently, a ribosomal frameshift site
was identiﬁed in the JEV serogroup that gives rise to the NS10 pro-
tein, an elongated form of NS1 protein (Firth and Atkins, 2009;
Melian et al., 2010; Ye et al., 2012).
It has been known for years that the RNA of many positive-
strand RNA viruses, including ﬂaviviruses, is infectious when trans-
fected into susceptible tissue culture cells (Baltimore, 1971a,b;
Boyer and Haenni, 1994). The ﬁrst reports of the infectivity of ani-
mal virus nucleic acids were made in 1957 by Colter et al. for
Mengovirus, Poliovirus and WNV and by Wecker and Schafer for
Eastern equine encephalitis virus (Colter et al., 1957; Wecker and
Schafer, 1957). This principle has been exploited as molecular tech-
niques have improved. A bacterial DNA plasmid clone containing
the full-length complementary DNA (cDNA) of a positive-strand
RNA virus and a suitable promoter, such as T7 can be used to pro-
duce infectious genomic viral RNA by in vitro transcription. These
DNA clones enable the introduction of mutations into viral gen-
omes and the consequent study of the resulting phenotype
(Ruggli and Rice, 1999). This powerful molecular tool is frequently
referred to as reverse genetics.Infectious DNA clones have been obtained and used to study
important virus properties such as virulence/attenuation, cell
penetration, replication, host range and functions of coding or
non-coding genomic regions. However, their construction is often
difﬁcult, involving cloning of many subgenomic cDNA fragments.
In spite of recent improvements afforded by novel molecular
techniques, the process is still laborious and many difﬁculties
remain including instability and toxicity of some viral sequences
in bacterial hosts (Gritsun and Gould, 1995; Rice et al., 1989;
Ruggli and Rice, 1999).
The aim of this review is to describe the important historical
steps in the development of ﬂavivirus infectious clones, to summa-
rize the different reverse genetics strategies that are currently used
and to assess the impact of this technology on our understanding
and control of these viruses and their diseases.
2. From past to present
In 1981, Racaniello et al. showed for the ﬁrst time that the full
length cDNA of a eukaryotic positive stranded RNA virus, the polio-
virus, can generate infectious virus in mammalian cells directly
after transfection (Racaniello and Baltimore, 1981b). This was
achieved by cloning the complete genome as 3 separate segments
(Racaniello and Baltimore, 1981a) and then producing a complete
cDNA copy of the genome in a bacterial plasmid. Cultured mamma-
lian cells transfected with this plasmid produced infectious
poliovirus.
Subsequently the development of the polymerase chain reac-
tion (PCR) in 1986 marked a turning point in infectious clone tech-
nology as it completely simpliﬁed the methodology for cloning; it
was no longer necessary to extract large quantities of viral RNA
from infectious cultures for reverse transcription (Mullis et al.,
1986). With the development of in vitro transcription systems
and the use of bacteriophage promoters (SP6, T7), it also became
possible to synthesize in vitro full length viral RNA with a much
higher efﬁciency when compared with cDNA transcription in the
cell. Furthermore, development of more efﬁcient transfection
methodologies, such as the use of cationic liposomes (Malone
et al., 1989) and electroporation, improved the efﬁciency of RNA
transfection of cultured cells. Thus, the basic methodology for
reverse genetics technology was established.
The ﬁrst reverse genetics model for the study of ﬂaviviruses was
published in 1989 (Rice et al., 1989). As for poliovirus, the com-
plete genome sequence of the YFV 17D vaccine strain was deter-
mined (Rice et al., 1985) resulting in a profound reorganization
of the classiﬁcation of arboviruses (ﬂaviviruses and alphaviruses
were assigned to different families using data from their genome
organization). During this developmental work, cloning the com-
plete genome into bacterial plasmids proved to be impossible
due to instability of the construct in Escherichia coli. This difﬁculty
was circumvented by cloning two segments of the genome in sep-
arate plasmids. They were then assembled by in vitro ligation and
ampliﬁed by in vitro transcription before transfection into cells
(Rice et al., 1989).
Subsequently, reverse genetics models were described for a
number of other ﬂaviviruses, namely JEV (Sumiyoshi et al., 1992),
DENV (Gualano et al., 1998; Kapoor et al., 1995; Kinney et al.,
1997; Lai et al., 1991; Polo et al., 1997; Puri et al., 2000), Kunjin
Fig. 1. Generic procedure for infectious clone construction. A double stranded cDNA
copy of an RNA virus genome is stably incorporated into a vector and ampliﬁed into
a host. After puriﬁcation of the construction, infectious viruses are obtained either
by direct transfection of permissive cells when an eukaryotic promoter is used or by
transfection of genomic RNA obtained by in vitro transcription when a bacterio-
phage promoter is used.
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virus (MVV) (Hurrelbrink et al., 1999), TBEV (Mandl et al., 1997)
and WNV (Yamshchikov et al., 2001b). As for the YFV 17D vaccine
strain, it was not always possible to obtain full-length cDNA cloned
in a single plasmid (e.g., for JEV and DENV2 (Kapoor et al., 1995;
Sumiyoshi et al., 1992). Thus, two clones containing roughly half
of the genomic cDNA were generally used. At this stage of the
development period many steps, including sub-cloning, correction
of mutations introduced by error-prone DNA polymerase, exchang-
ing plasmid backbone, were required often involving several years
additional work.
From the late 1980s, the race to obtain reverse genetics models
for ﬂaviviruses took advantage of many technological advances
and new strategies were described to circumvent the difﬁculties
(Edmonds et al., 2013; Gritsun and Gould, 1995; Khromykh et al.,
2001; Rice et al., 1989; Ruggli and Rice, 1999). For example, the
development of the PCR as well as the reverse transcription PCR
(RT-PCR) and in particular their improvements in terms of ﬁdelity,
processivity and speed, was a paradigm shift (Barnes, 1994; Cheng
et al., 1994; Gritsun and Gould, 1995, 1998). These improvements
encouraged virologists to develop a variety of reverse genetic sys-
tems. However, commercial kits were not available; consequently
scientists had to develop their own protocols. The development
and availability of reliable commercial molecular biology kits has
signiﬁcantly accelerated virological research capability.
During this developmental period a variety of methods were
reported to achieve similar objectives. For example, the use of long
high-ﬁdelity PCR combined with long RT provided a new approach
for the construction of recombinant viruses (Gritsun and Gould,
1995, 1998; Gritsun et al., 2001). The pioneering work of Gritsun
and Gould (1995) signiﬁcantly improved this method by using a
combination of primer sets and optimizing their concentrations
(Gritsun and Gould, 1995). They produced two long overlapping
PCR products (5.2 and 5.7 kb) by RT-PCR, ligated and transcribed
them into full-length viral RNA. Using this principle, infectious
full-length RNA transcripts were realizable even for situations in
which the virus genome could not easily be cloned in bacteria.
Moreover, it avoided the need for virus puriﬁcation and shortened
the time to produce engineered virus from years to days. However,
despite the success in generation of infectious transcripts from
long RT-PCR amplicons without cloning, a stable full-length clone
of virus genomes is still a valuable genetic resource for DNA (and
ultimately) RNA manipulation.
Improved sequencing methods were another essential require-
ment for the generation of reverse genetics models. Sanger’s
method (dideoxy or chain-termination) was the traditional
approach to DNA sequencing (Sanger et al., 1977). Initially, the
methods were completely manual and used radioactive ladders
displayed on huge acrylamide gels. Subsequently, the radioiso-
topes were replaced using four different ﬂuorescent dyes in the
sequencing reactions (Smith et al., 1985). This improvement rap-
idly led to the development of the ﬁrst automated ﬂuorescence
DNA sequencer (Ansorge et al., 1986, 1987; Brumbaugh et al.,
1988; Hood et al., 1987; Hunkapiller, 1991; Hunkapiller et al.,
1991; Prober et al., 1987; Smith, 1986). The next breakthrough
was made with the description of the ﬁrst high electric ﬁeld sepa-
rations of DNA sequencing fragments using capillary electrophore-
sis in 1990 (Swerdlow and Gesteland, 1990) and the ﬁrst
adaptation to display the results as an array (Zagursky and
McCormick, 1990). From this adaptation, the ﬁrst commercial
automated DNA sequencer that used capillary electrophoresis
rather than a slab gel, became available in 1996.
With these new automated machines the accumulation of DNA
sequence data accelerated rapidly. The early pioneer of sequence
databases was Margaret Dayhoff who had previously established
a protein sequence database and published the ﬁrst collection ofnucleotide sequence information in 1981 (Dayhoff et al., 1981).
Shortly thereafter, GenBank was created in 1982 by the National
Institute of Health, USA. GenBank provided a timely, centralized,
accessible repository for genetic sequences (Bilofsky et al., 1986).
In parallel with the growth of databases, methods to prepare
robust sequence alignments for detailed comparison soon became
the rate-limiting step in the analysis of sequence data. The devel-
opment of rapid search programs such as FASTA (Pearson and
Lipman, 1988) and BLAST (Altschul et al., 1990) made it practical
to identify genes in a new sequence by comparison with sequences
already in the databases. Bioinformatics which was in its infancy
suddenly became essential for the interpretation of these sequence
data and for the generation of testable hypotheses arising from the
data. The ﬁrst sequence analysis software then began to appear
such as MEGA which offered the possibility of producing phyloge-
netic trees from nucleotide and amino acid sequence alignments
(Kumar et al., 1994). The production of software for analysis of
sequence data is now a major growth industry, with new and
improved methods appearing frequently.
The automated Sanger DNA sequencing method is recognized as
the ‘‘ﬁrst-generation’’ technology, and newer DNA sequencing
methods are referred to as ‘‘next-generation’’ sequencing (NGS).
These new technologies utilize various strategies that rely on
Fig. 2. Bacteria-free approach, generic procedure for production of TBEV using Long
PCR. Two Long PCR products were either ligated using restriction enzymes or
merged by fusion PCR. After in vitro transcription and inoculation of the full-length
RNA transcripts intracerebrally into young mice, infectious viruses were recovered.
Fig. 3. Bacteria-free approach, generic procedure for production of KUNV using
CPEC reaction. Phusion high-ﬁdelity DNA polymerase was used to assemble and
incorporate multiple RT-PCR amplicons into a vector. The generated circular
product was then transfected directly into competent cells to recover infectious
viruses.
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imaging, high speed data analysis and throughput with the capac-
ity to produce enormous quantities of sequence data both rapidly
and at increasingly lower cost. The ﬁrst next-generation high-
throughput sequencing technology, the 454 FLX pyrosequencing
platforms, became available in 2005. By early 2007, Illumina had
released the Genome Analyzer, then SOLiD was released (Glenn,
2011). This technological aspect of sequencing and analysis is
expanding rapidly with novel and improved platforms continu-
ously being developed and released. The most recent examples
include Heliscope and Ion Torrent PGM which became available
in 2010. An important consequence of these developments is that
complete sequences can now be obtained rapidly regardless of ori-
gin, and whether or not they are already known. This rapid pro-
gress has totally altered the speed and ease with which reverse
genetics systems can be produced and used to study previously
inaccessible subjects.
DNA synthesis techniques and technologies are also evolving
rapidly to meet these new scientiﬁc demands. Entire genomes
can now be synthesized and as the demand has increased, de novo
synthesis has become a cheap alternative from which to obtain
cloned cDNA. One of many consequence of these improved meth-
odologies is that it is now technically possible to resuscitateviruses for which no infectious virions exist (Cello et al., 2002;
Tumpey et al., 2005) and in theory it should now be possible to cre-
ate novel viruses synthetically. This approach was ﬁrst explored by
Blight et al. (2000) for the creation of a replication-competent HCV
RNA replicon (Blight et al., 2000).
During the early stages of development in the 1980s, a lack of
adapted technologies and time constraints were the primary obsta-
cles for generating reverse genetics models. Today, the production
of a reverse genetic system is a relatively simple step towards
understanding the mechanisms governing the biological functions
of viruses.3. Flavivirus reverse genetics systems and construction
strategies
Reverse genetics is deﬁned as the generation of a virus entirely
from cDNA (Neumann and Kawaoka, 2004). It is a powerful tool
when studying viruses because they are relatively easy to manipu-
late technically and their short virus replication cycles facilitate
Fig. 4. Bacteria-free approach, generic procedure for production of DENV using
Gibson assembly method. Using a combination of three enzymes (exonuclease, DNA
polymerase and DNA ligase), multiple RT-PCR amplicons of both virus and vector
are assembled during an isothermal and single-reaction. The generated circular
product was then transfected directly into competent cells to recover infectious
viruses.
Fig. 5. Bacteria-free approach, generic procedure for production of ﬂaviviruses
using the ISA method. The entire viral genome, ﬂanked at the 50 extremity by the
human cytomegalovirus promoter (pCMV) and at the 30 extremity by the hepatitis
delta ribozyme followed by the simian virus 40 polyadenylation signal (HDR/
SV40pA), was ampliﬁed by PCR in three overlapping cDNA fragments. Direct
transfection of PCR products into competent cells enabled the recovery of infectious
viruses (successfully applied to DENV, YFV, JEV and TBEV).
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use as vaccines or vectors, for analysis of viral genes, non-coding
sequences or even for studies of life cycles, pathogenesis or trans-
mission. The most commonly used and powerful reverse genetics
system for studies of ﬂaviviruses is known as ‘‘infectious clone’’
(see Fig. 1), but other alternative systems have been developed
and are described below (see Figs. 2–5).3.1. Infectious clones
An infectious clone is a cDNA copy of an RNA virus genome that
can be stably incorporated into a vector and from which genomic
RNA can be obtained by in vitro transcription. Because this RNA
is potentially infectious, its transfection into appropriate cells leads
to the recovery of infectious virus. To manipulate these viruses
genetically, a cDNA copy of the RNA genome is cloned. If required,
this cDNA can then be modiﬁed by site-directed mutagenesis or de
novo synthesis, using residual or introduced restriction sites.
Appropriate plasmids, cosmids, bacteria or a variety of yeasts,
can be used as vectors to clone this cDNA. The presence of a DNA
dependant RNA polymerase promoter at the 50 end of the sequenceis required to enable efﬁcient generation of viral RNA either by
in vitro transcription of the cDNA or by direct transfection into per-
missive cells (Ruggli and Rice, 1999) (see Fig. 1). Transfection of
transcribed genomic RNA, by direct in vivo inoculation of suscepti-
ble animals, has also been shown to rescue infectious virus
(Gritsun and Gould, 1995) (see Fig. 2). In some cases, an antige-
nomic hepatitis delta virus ribozyme has been added at the 30
end of the viral genome (Perrotta and Been, 1991). The ribozyme
sequence is self-cleaved in cells and leaves the entire viral RNA
genome intact and available for replication by the cellular
machinery.
Whilst ﬂavivirus infectious clones provide a powerful tool for
studying many aspects of viruses, their construction as full-length
cDNA molecules in bacterial vectors can be problematic, laborious
and time consuming because they are often unstable, contain
unwanted induced substitutions and may be toxic for bacteria
due to viral protein expression. Various approaches have been
employed to overcome these problems using different hosts, vec-
tors, promoters or strategies to mutate cryptic bacterial promoter
sites in the ﬂavivirus genome.
3.1.1. Production of cDNA
Once the complete sequence of the genome is known, or alter-
natively the extreme 50 and 30 ends of the genome are known,
obtaining a pool of high ﬁdelity full-length cDNA is the ﬁrst step
in producing an infectious clone. Early methods usually used
sub-cloning steps with the production of short cDNA fragments
which were then linked together by ligation before being cloned
as full-length cDNA molecules or in the case of the ﬁrst ﬂavivirus
infectious clone, by the use of two plasmids and an in vitro ligation
method to assemble full length templates for transcription (Lai
et al., 1991; Rice et al., 1989). Subsequently, improvements in
PCR enzyme ﬁdelity and optimization of reaction conditions, led
to major increases in the achievable length of authentic cDNA
amplicons, ﬁnally enabling rapid ampliﬁcation of genomic length
cDNA (Barnes, 1994; Gritsun and Gould, 1995). As indicated
72 F. Aubry et al. / Antiviral Research 114 (2015) 67–85earlier, de novo synthesis of genomic length cDNA is now possible
but currently is not the ﬁrst method of choice. Regardless of which
method is used, the sequence of the entire genome of the derived
infectious clone must be determined and compared with the par-
ent virus.
3.1.2. Choice of host for cloning the cDNA
3.1.2.1. Bacteria.
3.1.2.1.1. Different strains. The E. coli expression system is the most
commonly used expression system for cloning of cDNA. The phys-
iology and genetics of these bacteria are well-deﬁned and a variety
of different host strains with various genetic backgrounds are
available giving them different speciﬁc characteristics to maximize
the chance of successful cloning (Casali, 2003). Optimized strains
may be selected because they contain one or more of several differ-
ent antibiotic resistance genes (e.g., Chloramphenicol, Ampicillin,
Tetracycline, Streptomycin), carry a chromosomal copy of a gene
like the T7 RNA polymerase gene (BL21), can be speciﬁcally
designed to clone large fragments of DNA (DH1, Topp-10), possess
or do not possess speciﬁed restriction-modiﬁcation systems or
grow very fast (DH5a turbo). Some strains also harbor mutations
that decrease the efﬁciency or invalid the recombination systems
thus increasing the integrity of cloned DNAwhen direct or inverted
repeats are present, have a high transformation efﬁciency (Nova-
Blue), do not methylate DNA (DM1) or even reduce the copy num-
ber of the plasmid for toxic proteins (ABLE C).
However, there is no perfect universal strain capable of amplify-
ing with limited toxicity, any ﬂavivirus infectious clone and it is
therefore necessary to determine empirically which one is the most
suitable for the sequence and the vector used. Thus different E. coli
strains have been used to construct stable full-length DENV-4 cDNA
(Lai et al., 1991) DENV1–4 chimeric virus (Bray and Lai, 1991),
DENV-2 (Blaney et al., 2004a), DENV-3 (Blaney et al., 2004b), or
TBEV (Pletnev et al., 1992). The strains used for the construction
of the ﬁrst major ﬂavivirus infectious clones were previously
described byNicolas Ruggli andCharles Rice (Ruggli andRice, 1999).
3.1.2.1.2. Different vectors. Since the beginning of molecular
cloning in the early 1970s, the number of vectors created has
increased enormously. Therefore, optimal vector choice is difﬁcult
but important to increase the success of obtaining the ﬁnal con-
struct. A variety of criteria should be taken into account such as
the insert size, the copy number or the selectable marker.
Plasmid: The maintenance and propagation of plasmids into E.
coli cells is an inefﬁcient process because cells that do not contain
a plasmid are at a growth advantage over those that do, given that
they have to replicate both the chromosome and additional plas-
mid DNA. A method of selecting cells that have received a plasmid
is therefore required and an appropriate selective pressure must be
imposed for maintenance and enhancement of the plasmid. Almost
all conventional plasmids use an antibiotic resistance gene, carried
on the backbone of the vector, as a selectable marker. Thus, the
addition of the appropriate antibiotic to the growth medium will
kill the cells that do not contain the plasmid and produce a culture
in which all cells do contain a plasmid. In many cases, the choice of
antibiotic is not restricted. However, some cloning strains of E. coli
are inherently resistant to some antibiotics. Thus, in these cases
these antibiotics cannot be used to select cells carrying the plasmid
of interest. The genotype of the desired cloning strain should be
checked prior to cloning.
In theory, most general cloning plasmids can carry a DNA insert
up to around 15 kb in size. Inserts in excess of this size may place
constraints on efﬁcient replication of the plasmids (particularly for
high-copy-number vectors) and can cause problems with insert
stability. Several types of vectors are available for cloning larger
fragments of DNA.Plasmids are maintained at different copy numbers, depending
on the origin of replication. In the majority of cases in which a piece
of DNA is cloned for conservation and ampliﬁcation for subsequent
manipulation, high yields of recombinant plasmid from E. coli cul-
tures, are the preferred choice. However, a high-copy-number
may cause problems for cloning DNA especially in the case of ﬂavi-
viruses for which there exist, within their genomes, one or more
cryptic prokaryotic promoters that facilitate the production of viral
proteins which can be toxic to bacteria at high levels. Even if the
protein is expressed poorly from the cloned DNA, the presence of
many copies of the plasmid may raise the level of protein to toxic
levels. In cases when recombinants are still obtained, their growth
rate is often frustratingly slow, and the cloned foreign DNA
sequences are often unstable (Blaney et al., 2006; Ruggli and Rice,
1999; Ward and Davidson, 2008). To solve these problems, low-
copy-number vectors have been developed in which tightly regu-
lated prokaryotic promoters are maintained at a low level of basal
expression and prokaryotic transcription terminators prevent spu-
rious transcription of foreign DNA sequences from upstream plas-
mid promoters.
This strategy has been used to obtain several infectious clones.
For example with TBEV, the cDNA was cloned into the low copy
number plasmid pBR322 (Gritsun and Gould, 1998) whereas the
Murray Valley encephalitis virus (MVEV) prototype strain 1-51
was inserted into the low-copy-number plasmid vector pMC18
(Hurrelbrink et al., 1999) and the complete full-length cDNA of
YFV was inserted under the control of an SP6 promoter in the
low copy number plasmid pACYC177 (Bredenbeek et al., 2003).
Similar approaches have been used for different strains of DENV-
2 (Gualano et al., 1998; Kinney et al., 1997; Polo et al., 1997; Zhu
et al., 2007), WNV (Shi et al., 2002; Yamshchikov et al., 2001b),
KUNV (Khromykh and Westaway, 1994) or TBEV (Mandl et al.,
1997). However, this does not always resolve the problem. For
example, several attempts to construct genetically stable JEV
cDNAs using low-, medium-, and high-copy-numbers of plasmids
or special bacterial hosts all failed (Mishin et al., 2001;
Sumiyoshi et al., 1992, 1995).
Bacterial artiﬁcial chromosome: Bacterial artiﬁcial chromosomes
(BAC) are circular DNAmolecules capable of maintaining very large
DNA inserts up to 350 kb and can be used, instead of plasmids, as
vectors for the assembly of infectious clones. They are based on
the E. coli fertility factor (F-factor) replicon which is maintained as
a circular supercoiled extra chromosomal single copy plasmid in
the bacterial host (Monaco and Larin, 1994; O’Connor et al., 1989;
Shizuya et al., 1992). Their high capacity suited their primary use
for the construction of infectious clones of large DNA viruses such
as baculoviruses (Luckow et al., 1993) or herpesvirus (Saeki et al.,
1998).
However, BAC technology has also been extended to ﬂavivi-
ruses. Thus, full-length JEV cDNAs were successfully obtained by
cloning the JEV genome into BAC vectors (Yun et al., 2003). The
same method was also applied to YFV (van der Most et al., 1999),
DENV-1 (Suzuki et al., 2007), and DENV-2 (Pierro et al., 2006;
Usme-Ciro et al., 2014) suggesting that this method was most sui-
ted to bacteria that could resist the toxicity caused by ﬂavivirus
genomes.
Cosmid: BAC and plasmids are not the only vectors that can be
used for infectious clone construction. Indeed, Zhang et al. (2001)
used a cosmid vector, Expand Vector I (Zhang et al., 2001). These
are conventional vectors that contain a small region of bacterio-
phage k DNA containing the cohesive end site (cos). These vectors
were designed to accommodate large inserts of 7–17 kb (Hohn and
Collins, 1980). They have proved to be more suitable for cloning
the full-length cDNA amplicon from JEV than other cloning vectors,
such as pBR322, pKS, pUC or pGEM.
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To efﬁciently generate viral RNAs from cDNA in vitro, in cellulo or
in vivo, the viral sequences need to be ﬂanked by a suitable pro-
moter. The most commonly used promoters for ﬂavivirus infec-
tious clones are the bacteriophage promoters T7 and SP6, and to
a lesser extent, the eukaryotic promoter of the human cytomegalo-
virus (referred here as CMV promoter) (see Fig. 1). Each has its own
advantages. Bacteriophage promoters are used in vitro to produce
large quantities of viral RNA from cDNA with bacteriophage RNA
polymerases. The transcripts are then transfected directly into per-
missive cells or animals, and infectious virus can be recovered. In
general, SP6 polymerase/promoters have lower efﬁciency than T7
in vitro transcription systems but under ideal conditions SP6 is
roughly comparable with the others. However, these RNA polymer-
ases are error prone, therefore, RNA transcripts cannot be viewed
as genetically homogeneous populations (Boyer et al., 1992;
Sooknanan et al., 1994).
The CMV promoter, on the other hand, enables viral RNA to be
produced in cellulo after direct transfection by full-length cDNAs in
eukaryotic cells. Such eukaryotic promoters have been successfully
used for the production of ‘‘infectious DNA’’ of two strains of WNV
(Khromykh et al., 2001; Pierson et al., 2005) as well as several posi-
tive strand RNA viruses, including polioviruses (Semler et al.,
1984), foot-and-mouth disease virus (Beard et al., 1999), several
alphaviruses (reviewed (Nougairede et al., 2013; Schlesinger and
Dubensky, 1999)), coronaviruses (Almazan et al., 2000) and plant
viruses (Boyer and Haenni, 1994; Johansen, 1996; Lopez-Moya
and Garcia, 2000). While the use of this promoter confers some
logistical advantages over bacteriophage promoters that require
the production of RNA in vitro, the problem of the stability and
the toxicity in bacteria still remain and are made particularly acute
in E. coli by the transcriptional activity of eukaryotic promoters
(Antonucci et al., 1989; Davis and Huang, 1988) while T7 and
SP6 promoters are not transcriptionally active in E. coli.
3.1.2.1.4. General problems involved in deriving infectious clones.
Construction of infectious clones enables direct genetic manipula-
tion of viral genomes and is a valuable tool of modern experimen-
tal virology. However, its use and practical importance are often
limited due to instability of the construct during propagation in
E. coli. This problem has been particularly evident when developing
ﬂavivirus infectious clones. As a consequence, some virus infec-
tious clones are either almost impossible to construct, or are very
difﬁcult to maintain in E. coli due to their predisposition to sponta-
neous rearrangements and/or to acquisition of stabilizing muta-
tions. The most plausible explanation is that such instability
results from unanticipated expression of viral cDNA encoding
products toxic to the bacterial host. Thus, different strategies have
been elaborated based on the observation that artiﬁcially intro-
duced deletions, insertions or frameshifts can alleviate the cloning
problems, either by increasing the stability of the construct,
decreasing the transcriptional activity of the promoter or the cryp-
tic expression of viral proteins.
Reduction of toxicity in bacteria: To circumvent the presence of
promoter-like sequences inside the viral genome or foreign gene
cassettes, advantage was taken of the major difference in mRNA
formation between prokaryotes and eukaryotes by using eukary-
otic RNA processing mechanisms as the essential part of the clone
stabilization strategy (Yamshchikov et al., 2001a). This approach
was conceived from the observation that a single nonsense muta-
tion, that result in the apparition of a premature stop codon, was
often sufﬁcient to stabilize the entire construct presumably by pre-
venting synthesis of toxic products. Hence, temporary ablation of
such deleterious expression at the translational level by interrupt-
ing the ORF, with the help of an intron containing stop codon(s),
was beneﬁcial during propagation of recombinant plasmids in
E. coli. The intron effectively blocked synthesis of toxic productsin the bacterial host, even if spurious transcription resulted in for-
mation of mRNA. Nuclear transcription in eukaryotic cells, accom-
panied by splicing of the primary transcripts, would lead to precise
excision of the intron and restoration of the original ORF. For virus
infectious clones and viral replicon-based expression vectors, sub-
sequent export of mRNA to the cytoplasm and its translation
resulted in synthesis of viral proteins, which initiated the viral
infectious cycle or replication of vector RNA. Using this approach,
deleterious effects of spurious transcription from eukaryotic pro-
moters in bacterial cells were eliminated at the translational level
by insertion of an intron(s) into viral cDNA cassettes. Nevertheless,
in some cases modiﬁcation of the viral cassette was not always fea-
sible possibly because the problem for implementation of the pro-
posed approach was associated with the potential existence of
cryptic splice sites in viral RNA genomes (Shiu et al., 1997). How-
ever, when potential sites were found this did not appear to have
a substantial impact on the functional properties of the designed
infectious DNA constructs.
Interruption of a viral open reading frame either by frameshift
mutations or insertion of introns leads to substantial stabilization
of plasmids containing viral genome cassettes under the control
of eukaryotic promoters (Johansen, 1996; Lopez-Moya and
Garcia, 2000; Olsen and Johansen, 2001). This suggests that spuri-
ous transcription from eukaryotic promoters in E. coli (Antonucci
et al., 1989; Davis and Huang, 1988) may substantially contribute
to the observed instability reported.
In another approach, the investigators tried to determine if a
decrease of spurious transcription could eliminate the destabiliz-
ing effect of eukaryotic promoters on ’’infectious DNA’’ constructs.
They thus described an alternative ‘‘minimal’’ approach based on
the manipulation of the promoter to minimize its activity in bacte-
ria and reduce its deleterious effects (Mishin et al., 2001).
The CMV promoter, often used to drive expression of engi-
neered constructs in a variety of mammalian cells (Foecking and
Hofstetter, 1986) consists of a transcriptionally active minimal
promoter region immediately adjacent to the RNA transcription
initiation codon, and an upstream enhancer element, which only
displays transcriptional activity in mammalian cells (Thomsen
et al., 1984). Using the knowledge that certain regulatory elements
of eukaryotic genes, such as enhancers, can inﬂuence gene expres-
sion in position- and orientation-independent manner (Jonsson
et al., 1994) the enhancer region was separated from the promoter
region and moved either directly upstream of the promoter or
immediately following the polyadenylation site. The deletion of
the enhancer led to a 5- to 6-fold reduction of gene expression.
In contrast, the relocalization of the CMV enhancer downstream
of the reporter gene had no discernible effect on gene production
in E. coli. Insertion of the CMV enhancer after the polyadenylation
signal resulted in a 10- to 100-fold increase of the transcription
rate in mammalian cells without affecting the stability of con-
structs in E. coli.
While this approach cannot resolve instability problems associ-
ated with the presence in viral genome of cDNA prokaryotic pro-
moter-like elements (Johansen, 1996; Lopez-Moya and Garcia,
2000; Olsen and Johansen, 2001), it provides, together with the
intron-based stabilization approach, ﬂexibility and a choice in the
design strategy.
Finally, Pu et al. (2011) developed a method for constructing
stable full-length ﬂavivirus cDNA by reducing the intrinsic toxicity
of the viral genome sequence in E. coli (Pu et al., 2011). They dem-
onstrated that the instability of the DENV-2 and JEV cDNA clones in
bacteria is due to the toxicity of the cryptic expression of viral pro-
teins by multiple putative E. coli promoter (ECP) sequences that are
embedded in the viral genome. Hence, they designed a new
approach to assembling infectious DENV-2 and JEV cDNA clones
by introducing silent mutations into the ECP sequences within
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activity, which resulted in the stabilization of the full-length
DENV-2 and JEV cDNA clones in E. coli.
Recently, a new approach to propagate DENV-2 and JEV infec-
tious cDNA clones in bacteria was described (Pu et al., 2014). Tan-
dem repeat sequences (seven repeated tetracycline-response
element (7XTRE)) were introduced upstream of a minimal CMV
promoter sequence (Cai et al., 2005) followed by the viral genome.
The cryptic expression of DENV-2 or JEV proteins in bacteria was
greatly reduced which increased stability to the cDNA clones with-
out altering the sequence of the viral genome.
Yeast: Some full-length ﬂaviviral cDNA genomes, unstable in E.
coli, were successfully cloned in eukaryotic systems which are
often more tolerant than bacteria to toxic ﬂavivirus sequences pre-
sumably because they promote less cryptic viral protein expres-
sion. The yeast Saccharomyces cerevisiae is a popular eukaryotic
host in cases for which viral cDNA was assembled by homologous
recombination. The two common strategies for cloning DNA in
yeast are the assembly of yeast artiﬁcial chromosomes (YACs)
and the use of yeast-E. coli shuttle vectors such as pRS424. Using
this approach, Polo et al. (1997) assembled full-length DENV-2
cDNA in yeast by recombination in vivo, followed by transforma-
tion of E. coli to produce plasmid DNA for in vitro transcription
(Polo et al., 1997). Similar approach have also been applied for
DENV-3 (Santos et al., 2013). Even if the problems with deleterious
effects and instability in the E. coli host were not completely elim-
inated, this method enabled recovery of infectious full-length RNA
transcripts. Of the two methods used to assemble the full-length
DENV clone, the shuttle vector approach was simpler and more
reliable than the YAC approach essentially due to the need of a sup-
plementary cloning step before the infectious clone could be recov-
ered from the YAC in bacteria. The samemethod has also been used
to assemble full-length DENV-1 (Puri et al., 2000) and DENV-4
(Kelly et al., 2010) cDNAs.
3.2. Bacteria-free approaches
Current methodologies for construction of infectious cDNA
clones are time-consuming, unpredictable and laborious processes
frequently associated with undesirable mutations or unstable/
toxic clones in bacteria. In order to avoid the need of using a bac-
terial host and thus to overcome the problems related to their use,
bacteria-free approaches have been developed.
3.2.1. Long PCR
Genetically engineered infectious viral RNA can be obtained by
direct transcription using a full-length cDNA template from either
a long RT-PCR or fusion of overlapping RT-PCR fragments without
cloning (see Fig. 2). Using this rapid approach, the problematic pro-
cess of construction of a full-length cDNA clone by repeated liga-
tion can be avoided and recombinant viruses can be made within
days.
This strategy was ﬁrst used by Gritsun and Gould (1995) for the
Siberian subtype Vs of the TBEV (Gritsun and Gould, 1995). The
procedure developed was based on the high ﬁdelity, high yield,
long PCR protocols described by Barnes (1994) and Cheng et al.
(1994) and utilized a mixture of two thermostable DNA polymer-
ases, one of which possessed a 30–50 exonuclease ‘‘proofreading’’
activity, to produce two overlapping cDNA products (5.7 and
5.2 kb in length) representing the full-length genome of the virus
(Barnes, 1994; Cheng et al., 1994). The 50 half of the cDNA was
designed to contain an SP6 promoter added in the ﬁrst forward pri-
mer. Full-length cDNA of Vs virus was then produced either by
ligation of the two overlapping DNA molecules in a unique
restriction site or by fusion PCR. When directly inoculated intra-
cerebrally into mice, the in vitro transcribed RNA from thesetemplates was infectious. This method avoided the need for virus
puriﬁcation and cDNA cloning procedures and shortened the time
to produce engineered virus from years to days. This was the
ﬁrst report in which an infectious RNA virus has been derived
by PCR without intermediate cloning of the cDNA in microbial
vectors.3.2.2. Circular polymerase extension reaction and Gibson assembly
As an alternative, Edmonds et al. (2013) developed another
approach for rapid generation of KUNV infectious cDNAs that
completely eliminates the need of plasmid DNA propagation in
bacteria and in vitro RNA transcription (Edmonds et al., 2013)
(see Fig. 3).
This approach is based on using a circular polymerase extension
cloning (CPEC) reaction with Phusion high-ﬁdelity DNA polymer-
ase to assemble multiple RT-PCR amplicons in the right order in
a vector. For that purpose, the RT-PCR fragments contain overlap-
ping ends and the ﬁrst and the last RT-PCR amplicons also have
overlapping ends with the vector fragment to ensure that when
the fragments and the vector are mixed and denatured, the over-
lapping ends anneal to each other. DNA polymerase then extends
the fragments, using the neighboring fragment as a primer. If the
overlapping fragments are designed to have similar annealing tem-
peratures, this reaction generates a circular end product. The gen-
erated circular product can then be transfected directly into
competent cells without any additional manipulations since the
in vitro RNA transcription step was eliminated by replacing SP6
or T7 polymerase promoters with the CMV promoter, thus allow-
ing transcription of viral RNA in cells directly from plasmid DNAs
by the cellular RNA polymerase II (Edmonds et al., 2013).
Based on the same principle, Siridechadilok et al. (2013) used
the Gibson assembly, a combination of three enzymes activity
(exonuclease, DNA polymerase and DNA ligase) to assemble multi-
ple overlapping DNA fragments in an isothermal and single-reac-
tion, to reconstruct the DENV genome from multiple PCR
products, ampliﬁed from cDNA, onto an expression plasmid with
a CMV promoter that precisely initiated transcription on the virus
genome sequence and a terminator, such as hepatitis D virus
(HDV) ribozyme that accurately generated 30 end of the transcribed
viral RNA (Siridechadilok et al., 2013) (see Fig. 4).3.2.3. Infectious subgenomic amplicons
Recently, Aubry et al. (2014) described a new reverse genetics
method designated ISA (Infectious-Subgenomic-Amplicons) that
facilitates the production of infectious wild-type or genetically
modiﬁed animal RNA viruses from genomic DNA material, in a
variety of forms, including pre-existing infectious clones, viral
RNA or de novo synthesized DNA genomic sequences (Aubry
et al., 2014) (see Fig. 5). This procedure does not require cloning,
propagation of cDNA into bacteria or in vitro RNA transcription.
Entire genomes have been ampliﬁed by PCR in 3 DNA fragments
of approximately 4 kb, each with 70–100 bp overlapping regions.
The ﬁrst and last fragments were ﬂanked respectively in 50 and 30
by the CMV promoter and the hepatitis delta ribozyme followed
by the simian virus 40 polyadenylation signal. PCR products were
mixed and transfected into permissive cells which enabled the
recovery of infectious viruses. Unlike other bacterium free
approaches, the ISA method does not require any additional step
beside the PCR ampliﬁcation needed to obtain the different cDNA
fragments. Instead, the process proceeds naturally by in cellulo
recombination, which greatly facilitates and shortens the
procedure.
In the initial study, the method was successfully used for WNV,
YFV, JEV, TBEV, DENV, Chikungunya virus (Alphavirus) and Coxsac-
kievirus B3 (Picornavirus).
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4.1. Reverse genetics methods and clonality of viral populations
Viral RNA polymerases characteristically exhibit low ﬁdelity
which results in relatively high mutation rates during viral RNA
replication. Consequently, newly generated populations of most
RNA viruses are extremely heterogeneous. This intra-population
variability has been described as a ‘‘mutant spectrum’’. While the
phenotype of a given virus has been attributed to the consensus
sequence, it is now established that the mutant spectrum as a
whole, is responsible for the phenotype (Ciota et al., 2007;
Holmes and Moya, 2002). In the case of arboviruses, an additional
factor is involved. These viral agents alternate between arthropod
vectors and vertebrate hosts. Consequently, the mutant spectrum
is likely to reﬂect these selective constraints, resulting in variant
populations that ensure selection of phenotypes efﬁcient in repli-
cation and transmission between both hosts (Ciota et al., 2008,
2007; Coffey and Vignuzzi, 2011; Coffey et al., 2008).
Most current reverse genetic systems for engineering viruses
use cloning methods during the experimental procedure. The viral
cDNA is cloned into a vector (plasmid, BAC, cosmid), and infectious
viruses are then recovered either by in vitro transcription using bac-
teriophage RNA polymerase and transfection into permissive cells,
or they are directly recovered from transfected cells through the use
of a eukaryotic transcriptional promoter. The transfected cDNA
used to recover infectious viruses can be considered as clonal and
consequently, at this stage, the mutant spectrum present in the ori-
ginal virus population no longer exists. Currently, viral populations
approximating to clonality can be obtained using either of the fol-
lowing twomethods, production of viral genomic cDNA cloned into
a plasmid under the control of a eukaryote promoter or clonal sub-
genomic cDNA fragments (e.g., plasmid fragments used instead of
PCR products using the ISA method). Potential impacts arising from
the depletion of mutant spectra could result in modiﬁcation of the
viral phenotype. For example, it was observed that viruses recov-
ered using reverse genetics initiated from clonal populations, repli-
cated more slowly than their corresponding parent non-cloned
ancestors (Coffey and Vignuzzi, 2011; Kinney et al., 1997; Pierro
et al., 2006) or they exhibited reduced neurovirulence for rodents
(Hayasaka et al., 2004). However, based on consensus sequencing,
mutations could not be identiﬁed to account for these different
phenotypes. These examples illustrate some of the potential limita-
tions of the reverse genetics and sequencingmethods used to inves-
tigate the basis of virus pathogenesis.
In contrast, the new methods described above which do not
involve bacterial cloning of the viral cDNA, provide the opportunity
to conserve the mutant spectrum present in the original viral sam-
ple (e.g., a clinical sample or cell culture isolate) (Aubry et al., 2014;
Edmonds et al., 2013; Siridechadilok et al., 2013).Alternatively,
other methods can potentially generate genetic variability com-
pletely different from the initial diversity of the source material.
For example, error-prone DNA-dependent RNA polymerases such
as T7 or SP6 introduce random mutations during in vitro transcrip-
tion of viral RNA genomes from cloned cDNA. Moreover, DNA
dependent DNA polymerases can also generate errors. Thus, the
possible use of PCR enzymes that exhibit different levels of ﬁdelity
could be considered as a means of regulating the variant composi-
tion within the mutant spectrum and presumably, changing the
phenotype of the recovered virus. Indeed, one could visualize the
use of such methods to investigate the underlying basis of viral
pathogenesis and in the case of arboviruses to examine the impact
of altered mutant spectra on virus–vector–host interactions.
Keeping this in mind and at the same time wishing to exploit
the potential versatility of reverse genetics methods, one can
imagine how different questions need to be raised before theelaboration of any experiment. That will determine the choice of
the most suitable reverse genetic system, each one of them pos-
sessing its own advantages and drawbacks. For example, if the
objective is to study the effect of one mutation, working with a clo-
nal viral population could be appropriate and it would be advanta-
geous to work with infectious clones or an equivalent method.
However, if the objective is to study the interactions between host
and virus, then it would be interesting to use reverse genetics
methods that conserve the original mutant spectrum to mimic
more closely what is happening during the natural cycle of the
virus.4.2. Reverse genetics methods as research tools
Reverse genetics systems allow artiﬁcial manipulation of viral
genomes by site-directed mutagenesis, deletion/insertion, and
rearrangement. Studying the phenotype of the viruses generated
using these methods has allowed the scientiﬁc community to gain
valuable knowledge related to the replication, biological character-
istics, and pathogeneses of these viral agents. Here, we describe
recent selected advances arising from the study of ﬂaviviruses
based on the application of reverse genetics (Table 1) (earlier ﬁnd-
ings were described by Ruggli and Rice (Ruggli and Rice, 1999)).4.2.1. Studying point mutations
Reverse genetics enables high ﬁdelity production of infectious
viruses from cloned viral cDNA, by utilizing the very low mutation
rate of viral cDNA-bearing plasmids during their ampliﬁcation in
bacteria. This provides the possibility to investigate the conse-
quences on replicative ﬁtness of the introduction of a single muta-
tion. Accordingly, a large number of genetically deﬁned viral
mutants have been constructed to study a variety of ﬂaviviruses,
including YFV (Muylaert et al., 1997), DENV (Leardkamolkarn
et al., 2010; Matusan et al., 2001), JEV (Arroyo et al., 2001;
Sumiyoshi et al., 1995; Ye et al., 2012; Zhao et al., 2005), WNV
(Arroyo et al., 2004; Martin-Acebes et al., 2013; Van Slyke et al.,
2012) or TBEV (Gritsun et al., 2001; Mandl et al., 2000; Yoshii
et al., 2004).
As examples, point mutations engineered into the prM or E pro-
teins of DENV-2/WNV chimeric viruses have been shown to
improve viability and viral yields in cell cultures (Huang et al.,
2005). DENV-2 viruses containing single point substitution in the
50 UTR exhibited reduced replicative ﬁtness in cellulo and reduced
neurovirulence for newborn mice (Leardkamolkarn et al., 2010).
This observation was conﬁrmed for several other ﬂaviviruses when
deletions were engineered into the 30 and 50 UTR causing attenua-
tion in cell culture and in animals (Blaney et al., 2010, 2008;
Cahour et al., 1995; Mandl et al., 1998; Men et al., 1996; Zeng
et al., 1998). Van Slyke et al. (2012) engineered point mutations
in the WNV NS5 gene which encodes the RNA polymerase (Van
Slyke et al., 2012). The point mutations were positioned remote
from the polymerase active site. This resulted in reduced replica-
tive ﬁtness in cellulo and attenuation of neurovirulence in vivo. Five
shared point mutations were introduced in the hinge region span-
ning domains I and II of the E glycoprotein of JEV (residues E107,
E138, E279, E315, E439) and WNV (residues E107, E138, and the
corresponding E280, E316 and E440) (Arroyo et al., 2001, 2004)
and also 3 mutations were introduced in the upperlateral surface
of domain III of TBEV (residues E308, E310, E311) (Mandl et al.,
2000). In each of these examples the viruses showed reduced neu-
rovirulence in mice. However, the single mutation located in the
hinge region, E279, of JEV increased neurovirulence (Monath
et al., 2002). Thus, each study identiﬁed a direct association
between a speciﬁc viral genomic region or speciﬁc site and the cor-
responding biological properties of the virus.
Table 1
List of the different studies quoted in Section 4 .
Impact/utilisations Virus References
Single mutations YFV Muylaert et al. (1997)
DENV Blaney et al. (2008, 2010), Cahour et al. (1995), de Wispelaere and Yang (2012), Huang et al. (2005), Hung et al. (2004),
Leardkamolkarn et al. (2010), Matusan et al. (2001), Men et al. (1996), Modis et al. (2004) and Zeng et al. (1998);
JEV Arroyo et al. (2001), Liang et al. (2009), Lin et al. (2006), Liu et al. (2004), Monath et al. (2002), Sumiyoshi et al. (1995)
and Ye et al. (2012)
WNV Arroyo et al. (2004), Huang et al. (2005), Martin-Acebes et al. (2013) and Van Slyke et al. (2012)
TBEV Gritsun et al. (2001), Mandl et al. (1998, 2000) and Yoshii et al. (2004)
MVEV Hurrelbrink and McMinn (2001)
Virulence determinants DENV Bray et al. (1998), Grant et al. (2011), Gualano et al. (1998), Hanley et al. (2002), Leardkamolkarn et al. (2010) and
Prestwood et al. (2008)
JEV Tajima et al. (2010) and Yamaguchi et al. (2011)
WNV Audsley et al. (2011), Borisevich et al. (2006), Pijlman et al. (2008), Shirato et al. (2004), Whiteman et al. (2011), Wicker
et al. (2006, 2012), Yu et al. (2008) and Zhang et al. (2006)
TBEV Mandl (2005)
LGTV Rumyantsev et al. (2006)
KUNV Audsley et al. (2011) and Liu et al. (2006)
Virus/host cell machinery
interactions
DENV Duan et al. (2008)
WNV Davis et al. (2007) and Emara et al. (2008)
Mechanisms of viral immune
evasion
WNV Liu et al. (2006) and Schuessler et al. (2012)
Host speciﬁcity YFV Charlier et al. (2010)
DENV Charlier et al. (2010) and Tumban et al. (2011)
WNV Saiyasombat et al. (2014)
LGTV Tumban et al. (2011) and Saiyasombat et al. (2014)
MODV Charlier et al. (2010) and Saiyasombat et al. (2014)
Reporter genes DENV Schoggins et al. (2012) and Zou et al. (2011)
WNV Pierson et al. (2005) and Puig-Basagoiti et al. (2005)
Viral proteins DENV Crabtree et al. (2005), Erb et al. (2010), Pryor and Wright (1993, 1994) and Pryor et al. (1998)
WNV Beasley et al. (2005)
TBEV Koﬂer et al. (2003)
KUNV Hall et al. (1999) and Liu et al. (2003)
MVEV Clark et al. (2007)
Cyclization sequences and RNA
secondary structures
YFV Bredenbeek et al. (2003)
DENV Alvarez et al. (2008), Liu et al. (2013) and Men et al. (1996)
TBEV Mandl et al. (1998) and Tuplin et al. (2011)
KUNV Khromykh and Westaway (1997)
Chimeric vaccines YFV Arroyo et al. (2004), Caufour et al. (2001), Chambers et al. (1999), Guirakhoo et al. (2000, 2001, 2006), Monath et al.
(1999, 2001, 2003, 2006), Pugachev et al. (2004) and Van Der Most et al. (2000);
DENV Bray and Lai (1991), Bray et al. (1996, 1998), Caufour et al. (2001), Chen et al. (1995), Guirakhoo et al. (2000, 2001,
2006), Li et al. (2013a), Maximova et al. (2014), Pletnev et al. (2002) and Van Der Most et al. (2000)
JEV Chambers et al. (1999), Li et al. (2013a,b) and Monath et al. (1999, 2003)
WNV Arroyo et al. (2004), Li et al. (2013b), Maximova et al. (2014), Monath et al. (2001, 2006), Pletnev et al. (2002) andWang
et al. (2014)
TBEV Wang et al. (2014)
SLEV Pugachev et al. (2004)
Antivirals DENV Qing et al. (2010) and Yang et al. (2014)
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replication or virulence characteristics, reverse genetics has also
enabled precise identiﬁcation of the speciﬁc stage within the viral
replication cycle that is altered. In a remarkable example of this, a
silent mutation in the NS2A gene of the vaccine strain of JEV (JEV-
SA-14-14-2) has been shown to abolish the formation of the large
NS10 protein by destabilizing a conserved RNA pseudoknot second-
ary structure responsible for the occurrence of a ribosomal frame-
shift, thus reducing neurovirulence and neuroinvasiveness in mice
(Ye et al., 2012). In another study, mutation E138K in JEV domain I
of the E protein, had a direct impact on viral spread from cell to cell
by increasing virus-cell interactions and decreasing viral entry efﬁ-
ciency (Zhao et al., 2005) resulting in reduced expression kinetics
of viral proteins, including the NS5 protein, an Interferon (IFN)
antagonist (Lin et al., 2006), which in turn, leads to reduced capac-
ity to block IFN signaling and increases the attenuation phenotype
(Liang et al., 2009). Other studies on JEV, MVEV and DENV have
indicated that mutations in domains II and III of the E protein
can impair virus binding and entry into host cells (Hung et al.,2004; Hurrelbrink and McMinn, 2001; Liu et al., 2004; Modis
et al., 2004). More recently, De Wispelaere and Yang (2012)
showed that mutation of three conserved residues in the Domain
I/Domain III linker of the DENV-2 E protein greatly impaired viral
production by abolishing formation of viral particles within the
cells (de Wispelaere and Yang, 2012).
4.2.2. Host/pathogen interactions
The ease with which infectious clones can now be genetically
modiﬁed has provided the opportunity to gain new insights into
the nature of virus–host interactions in the context of virulence
determinants, virus–host cell interactions and the mechanisms of
evasion that underly host speciﬁcity.
4.2.2.1. Virulence determinants. By introducing mutations or con-
structing intratypic/heterotypic chimeric viruses, numerous viru-
lence determinants have been identiﬁed and analyzed to
understand the mechanistic basis behind these altered phenotypes
(reviews (Hurrelbrink and McMinn, 2003; Mandl, 2005)).
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that all members of the genus Flavivirus produce a unique, abun-
dant, non-coding subgenomic RNA element (sfRNA), derived from
the 50-end of the 30 UTR that protects downstream RNA from deg-
radation by cellular ribonucleases (Pijlman et al., 2008). This sfRNA
has been shown to play an important role in the virus replication
cycle and contributes to viral cyto- and host-pathogenicity. Other
WNV genetically engineered viral mutants have been generated
to enable the identiﬁcation of a large number of virulence determi-
nants within the structural/non-structural genes and the 30 UTR of
the viral RNA genome (Audsley et al., 2011; Borisevich et al., 2006;
Liu et al., 2006; Shirato et al., 2004; Whiteman et al., 2011; Wicker
et al., 2006, 2012; Yu et al., 2008; Zhang et al., 2006).
Grant et al. (2011) showed that a single amino-acid substitution
NS4B-F52L in the mouse-virulent DENV-2 strain D2Y98P-PP1 sig-
niﬁcantly reduced the efﬁcacy of viral RNA synthesis in mamma-
lian cells and completely abolished the virulence/pathogenesis in
an AG129 mouse model (Grant et al., 2011). They also showed that
the reverse substitution in a non-virulent DENV-2 strain TSV01
was sufﬁcient to make this strain virulent in the same mouse
model. Several other viral determinants modulating the intrinsic
virulence of DENV, for mice, have been identiﬁed and shown to
affect either the replication efﬁciency (Leardkamolkarn et al.,
2010) or the binding properties (Bray et al., 1998; Gualano et al.,
1998; Prestwood et al., 2008). Similar results were obtained with
the JEV strain Mie/41/2002 in which the E-S123R amino-acid sub-
stitution exhibited increased virulence for mice (Tajima et al.,
2010). Notably, a correlation between growth properties in cellulo
and virulence in vivo was not always observed. Indeed,
Yamaguchi et al. (2011) revealed that an amino acid substitution
NS4A-V3I of the JEV strain Mie/40/2004 increased its virulence in
mice without inﬂuencing the growth rate in cell culture
(Yamaguchi et al., 2011).
Molecular determinants of neuroinvasiveness and neuroviru-
lence have also been studied. Rumyantsev et al. (2006) demon-
strated inhibition of neuroinvasiveness with Langat virus (LGTV)
strain TP21 and identiﬁed 4 amino acid substitutions located either
in the E protein (S267L; K315E; N389D) or the NS3 protein (K46E)
that are independently responsible for the abolition of neuroinva-
siveness (Rumyantsev et al., 2006). Likewise, Hanley et al. (demon-
strated that replacement of several paired charged amino acids, by
alanine, in the NS5 polymerase protein decreased DENV-4 neurovi-
rulence in suckling mice (Hanley et al., 2002)). Moreover, a large
number of speciﬁc mutations in the E protein domains of TBEV,
JEV, MVEV or YFV have been shown to affect either neuroinvasive-
ness or neurovirulence in mice (reviews (Hurrelbrink and McMinn,
2003; Mandl, 2005)).
4.2.2.2. Virus/host cell machinery interactions. By the introduction of
various amino acid substitutions into the Elongation factor 1-alpha
(eEF1A) binding site or into adjacent areas of the 30-terminal Stem–
Loop (30 SL) in the 30 UTR of a WNV infectious clone, it was shown
that mutations which decreased the binding efﬁciency of eEF1A to
the viral 30 SL in vitro had a negative effect on viral minus-strand
RNA synthesis in cellulo and vice versa for mutations that increased
binding efﬁciency of eEF1A (Davis et al., 2007). They also showed
that eEF1A co-localized with viral replication complexes in
infected cells which strongly suggest that interaction between
the cellular protein eEF1a and the 30 SL of the WNV genomic
RNA facilitates viral minus-strand RNA synthesis.
Other interactions between the 30 SL and host cellular factor
have been reported and their roles identiﬁed. Using an approach
similar to that described above, the interaction between the T-cell
intracellular antigen-related (TIAR) protein and T-cell intracellular
antigen-1 (TIA-1) protein with the WNV minus 30 SL RNA (30 ()SL
RNA) was characterized (Emara et al., 2008). Using in vitroexperiments the speciﬁc binding sites on the WNV 30 ()SL RNA
were identiﬁed and the effects of mutations on virus replication
within these binding sites were analyzed. The efﬁciency of geno-
mic RNA synthesis and virus production progressively decreased
with decreasing in vitro binding efﬁciency of TIAR/TIA-1 for mutant
30 ()SL RNAs. In these experiments neither TIA-1 nor TIAR was
found to bind to the 30 (+)SL or 50 (+)SL of the genomic RNA. The
fact that several mutant RNAs that inefﬁciently interacted with
TIAR/TIA-1 in vitro rapidly reverted in vivo, indicated that they
could replicate at a low level. This suggests that interaction
between TIAR/TIA-1 and the viral 30 ()SL RNA is not required
for initial low-level symmetric RNA replication but instead facili-
tates the subsequent asymmetric ampliﬁcation of genome RNA
from the minus-strand template.
In another study, the domains on prM protein that might be
responsible for its interaction with the vacuolar ATPase (V-ATPase)
were analyzed. Using several DENV with deletions in the prM
region, critical residues located in the pr portion of this protein
which are highly conserved among the members of ﬂavivirus and
responsible for the binding of the V-ATPase, were identiﬁed
(Duan et al., 2008). The use of a speciﬁc inhibitor of V-ATPase that
inhibits endosome and lysosome acidiﬁcation demonstrated that
this interaction plays an important role in mediating low-pH
dependent entry of DENV and also in establishing a suitable pH
environment that will facilitate efﬁcient virus secretion.
4.2.2.3. Mechanisms of viral immune evasion. Research that focuses
on identiﬁcation and understanding of the mechanisms involved
in viral evasion of host immune responses has also beneﬁted signif-
icantly through the development of improved reverse genetics
methodologies. Thus, it was demonstrated that incorporation of
an NS2A-A30P mutation into the KUNV genome results in a mutant
virus that elicits more rapid induction and higher levels of synthesis
of IFN-a/b in infected human A549 cells when compared with
unmodiﬁed KUNV. This introduced mutation induces drastic dimi-
nution of KUNV neuroinvasiveness and neurovirulence in mice and
this virus was also partially attenuated in IFN-a/bc receptor knock-
out mice. Thus, the A30Pmutationmay also play a role in more efﬁ-
cient activation of other antiviral pathways (Liu et al., 2006).
It has also been shown that a mutant KUNV deﬁcient in the pro-
duction of sfRNA replicated poorly in WT mice and in Mouse
Embryonic Fibroblasts (MEFs). However, the virulence of the
mutant virus was largely rescued in mice with a combined deﬁ-
ciency in major factors involved in the type I IFN response, the
transcriptional regulators IRF-3 and IRF-7, which act downstream
of IPS-1 and MyD88, or a deﬁciency of the type I alpha/beta inter-
feron receptor (IFNAR) suggesting a contribution for sfRNA in over-
coming the antiviral response mediated by type I IFN (Schuessler
et al., 2012). Also, remaining differences in virulence between
WT and sfRNA-deﬁcient virus in IFN response-defective mice sug-
gest limited contribution of an IFN-independent antiviral response
in restricting virulence of sfRNA-deﬁcient virus.
4.2.2.4. Host speciﬁcity. Many of the recognized ﬂaviviruses are arb-
oviruses, i.e., they are transmitted to vertebrates by the bite of an
infected arthropod. However, others, including insect-speciﬁc ﬂa-
viviruses (ISFV) and non-known-vector (NKV) ﬂaviviruses are not
arboviruses. The viral determinants responsible for host tropism
and vector speciﬁcity remain largely undeﬁned. In order to explore
the role of the UTRs in host speciﬁcity, chimeric genomes were
generated in which the 50 UTR, capsid and/or 30 UTR encoding
regions of mosquito-borne DENV-4 were replaced, separately or
in combination, with those of tick-borne LGTV. None of the chime-
ric genomes yielded detectable virus following transfection.
Replacement of the variable region (VR) in the DENV-4 30 UTR
(DENV-4-LGTswapVR) with that of LGTV showed lower replication
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cells and was able to infect mosquitoes in vivo. Moreover, LGTV
was able to infect ticks while DENV-4 or DENV-4-LGTswapVR did
not (Tumban et al., 2011). These results suggest that UTRs cannot
be exchanged between tick-borne and mosquito-borne ﬂaviviruses
and that the 30 VR did not affect mode of transmission.
To study whether or not the viral E protein plays a role in the
(in)ability of ﬂaviviruses to infect mosquito cells, the replication
of two chimeric ﬂaviviruses was monitored. For these experiments,
the prM+E region or the AnchC+prM+E region of the mosquito-
borne ﬂaviviruses YFV-17D or the DENV-2 were replaced by the
corresponding region of the NKV ﬂavivirus Modoc virus (MODV).
These chimeric viruses replicated efﬁciently in mammalian
(Vero-B) and mosquito (C6/36) cells, whereas infectious MODV
RNA failed to replicate in mosquito cells (Charlier et al., 2010).
These observations suggest that the inability of NKV ﬂaviviruses
to replicate in arthropod cells is not determined by the viral E pro-
teins but appears to occur at a post-entry stage most likely due to
the differences in host protein proﬁles between mammalian and
arthropods cells. The results obtained by Saiyasombat et al.
(2014) using a similar approach corroborate these observations
and indicate that the vertebrate host speciﬁcity of MODV could
be conditioned by genetic elements located outside of the prM+E
region (Saiyasombat et al., 2014).
4.2.2.5. Reporter genes. The ability to monitor rapidly and quantita-
tively, virus replication by virtue of reporter gene activity provides
numerous applications for the analysis of different facets of ﬂavivi-
rus biology, both in vitro and in vivo. Indeed, a detection system,
such as a recombinant virus expressing a reporter gene that can
be monitored in real-time may shorten the amount of time needed
to conduct antiviral assays for the development of novel therapeu-
tics. Another powerful application is the study of virus tropism
in vivo. The reporter gene can be used to identify the initial cellular
targets during an infection, how these cells migrate after virus
exposure or the mechanism by which a virus can penetrate the
central nervous system.
Infectious molecular clones capable of expressing high levels of
a reporter gene in infected cells have also been described. Thus, the
gene encoding green ﬂuorescent protein (GFP) was cloned into the
30 UTR of the viral genome under the translational control of the
internal ribosome entry site (IRES) of encephalomyocarditis virus
(EMCV). Transfection of cells with this infectious DNA plasmid
resulted in the production of infectious WNV capable of mediating
high-level expression of GFP in several different cell types (Pierson
et al., 2005). This approach has also been used to clone a Renilla
luciferase reporter gene (Puig-Basagoiti et al., 2005).
Zou et al. (2011) on the other hand, used a different approach to
construct a cDNA clone of DENV-2 that encodes the Renilla lucifer-
ase reporter gene (Zou et al., 2011). Indeed, a fragment encompass-
ing the ﬁrst 38 amino acids of the capsid protein, a Renilla
luciferase gene, and a 2A sequence from the foot-and-mouth dis-
ease virus (FMDV2A) was inserted at the junction between the 50
UTR and the ORF of the viral genome. The duplication of the N-ter-
minal 38 amino acids of the capsid protein was used to maintain
RNA elements that are required for genome cyclization (Alvarez
et al., 2008, 2005a; Friebe and Harris, 2010) while the FMDV2A
sequence was used to ensure that the luciferase protein was prop-
erly processed.
A similar approach was used by Schoggins et al. (2012) for the
generation of infectious DENV-2 that express either GFP or ﬁreﬂy
luciferase. These constructs were then used to follow the dynamics
of DENV infection in mice by bioluminescence imaging and iden-
tify IFN-stimulated genes (ISGs) with anti-DENV activity by screen-
ing the DENV-GFP against a library of more than 350 ISGs
(Schoggins et al., 2012).However, it is worth noting that although these constructs pres-
ent great potential, they often remained unstable through contin-
uous cell passaging and/or exhibited decreased ﬁtness compared
to wild-type.
4.2.3. Viral proteins
4.2.3.1. Functions of NS2A and NS3 proteins. Two amino acid substi-
tutions, NS2A-I59N and NS3-Y518H, that contributed to severely
impaired generation of virus infectivity were identiﬁed in reverse
genetics studies that utilized the infectious clone of KUNV (Liu
et al., 2003). Using site-directed mutagenesis, it was demonstrated
that the mutation located in the NS3 protein induced severe inhi-
bition of RNA replication while the introduced mutation in the
NS2A protein blocked virus assembly and/or secretion. In addition,
sequence analysis of the recovered viruses showed that both
amino acids had reverted to the wild-type sequence demonstrating
the functional importance of these residues in viral replication
and/or viral assembly.
4.2.3.2. Importance of the capsid protein internal hydrophobic
domain. The isolation of viable mutants of TBEV carrying extend-
ing deletions in the capsid protein demonstrated that infectious
particles can be formed even if the entire central hydrophobic
domain is removed. However, these results showed that large dele-
tions were tolerated only following the acquisition of additional
mutations that increased the hydrophobicity of the protein sug-
gesting that they may compensate for the loss of the central hydro-
phobic domain (Koﬂer et al., 2003). These results corroborate the
notion that hydrophobic interactions of protein C are essential
for the assembly of infectious particles but illustrate that individ-
ual residues within the central hydrophobic domain are not abso-
lutely required for infectivity.
4.2.3.3. Importance of the domain-III FG loop for infection of mam-
malian and mosquito cells. An infectious clone of DENV-2 was used
to investigate the importance of the extended loop motif between
the F and G beta strands (FG loop) located in domain III (DIII) of the
E protein. By deleting or substituting amino acids in the loop to
mimic motifs present in other mosquito-borne or tick-borne ﬂavi-
viruses, it was shown that retention of the DIII FG loop structure is
important whereas the speciﬁc amino acid sequence can vary, pro-
viding the loop is maintained (Erb et al., 2010). These observations
related to viral infection and replication in mammalian cells as
well as in Aedes aegypti mosquito midguts, but not C6/36 cells
where the FG loop was found to be dispensable. All the FG loop
mutants were able to bind to and enter mammalian cells but rep-
lication of mutants mimicking the tick-borne FG-loop was delayed
in Vero cells at 37 C until secondary mutations appeared. These
ﬁnding emphasize the importance of the E protein DIII FG loop
structure in DENV infection and replication in mosquitoes and
mammalians cells.
4.2.4. Protein modiﬁcations
4.2.4.1. NS1. glycosylation. In order to investigate the importance of
NS1 protein glycosylations, site-directed mutagenesis of a full
length infectious clone of DENV-2 was used to create mutant
viruses lacking the NS1-130N, NS1-207N or both of these NS1 gly-
cosylation sites (Crabtree et al., 2005). The results showed that
viruses altered either at the Asn-130 or the Asn-207 position,
exhibited reduced growth characteristics in C6/36 cells, reduced
NS1 secretion from infected cells and decreased neurovirulence
in a mouse model. Ablation of both NS1 glycosylation sites resulted
in unstable viruses that acquired numerous additional mutations.
Taken together, these results indicated that glycosylation of the
DENV-2 virus NS1 protein may inﬂuence NS1 protein processing/
transport as well as the pathogenicity of the virus.
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from the WNV strain NY99, glycosylation within the E protein
was shown to enhance neuroinvasiveness in a mouse virulence
model (Beasley et al., 2005). The introduction of the prM-E genes
of the strain ETH76a, which is attenuated for mouse neuroinvasion
and possess the E-N154S mutation that abolished the glycosylation
motif at residue E154, into an infectious clone of the highly neuro-
invasive NY99 strain (E-154S in ETH76a and E-154N in NY99), or
speciﬁc mutation of residue E154 to only abolish glycosylation,
resulted in attenuation of that virus to a level comparable with
ETH76a. Furthermore, a mutation that permitted glycosylation of
the ETH76a E protein in the NY99 backbone yielded a virus with
virulence equivalent to NY99. These results conﬁrmed that the
highly virulent mouse neuroinvasion phenotype of strain NY99
compared to the attenuated mouse neuroinvasion phenotype of
strain ETH76a is primarily mediated via the presence of the E pro-
tein glycosylation motif.
4.2.4.3. Non-essential dimerisation of NS1. It was demonstrated in
1999, that a single amino acid substitution of a conserved proline
residue in the NS1 protein of KUNV (P250L) results in loss of dimer
formation, without inhibiting virus replication and the correct traf-
ﬁcking of this protein in infected cells (Hall et al., 1999). However,
virus yields were reduced and its virulence diminished. Contrary to
what was previously reported, these results demonstrated that
dimerisation of the ﬂavivirus NS1 protein is not an essential
requirement for NS1 protein secretion, virus replication and neuro-
virulence in mice (Pryor and Wright, 1993, 1994; Pryor et al.,
1998). These observations were conﬁrmed when it was shown that
a homologous substitution at residue 250 of MVEV NS1 protein
also abolished NS1 dimerization but replication efﬁciency of the
mutant virus was reduced in mammalian cells and neuroinvasive-
ness was reduced in weanling mice (Clark et al., 2007).
4.2.5. Cyclization sequences and RNA secondary structures
4.2.5.1. Cyclization sequences. Using atomic force microscopy and
RNA binding assays, it was ﬁrst shown that the known 50 and 30
cyclization sequences present in all mosquito-borne ﬂaviviruses
(MBFV), were essential for the formation of RNA–RNA complex for-
mation (Alvarez et al., 2005b). However, additional complemen-
tary sequences present at the 50 end immediately Upstream of
the initiator AUG Region (UAR) and at the 30 end within the 30 SL
(50 and 30 UAR) of the viral RNA were also shown to be required.
In order to investigate the functional role of the 50–30 UAR, these
sequences were mutated either separately, to destroy base pairing,
or simultaneously, to restore complementarity in a DENV infec-
tious clone. Non-viable viruses were recovered after transfection
of DENV mutants carrying speciﬁc substitutions within the 50 or
30 UAR, while the mutant containing the compensatory mutations
that restore complementarity was able to replicate demonstrating
that base pairing of 50–30 UAR provides an essential element for
viral viability and that cyclization of the RNA is a required confor-
mation for viral replication (Alvarez et al., 2008).
4.2.5.2. Cis-acting element. Using structure prediction and bio-
chemical analysis, Liu et al. (2013) identiﬁed a novel conserved
cis-acting element, downstream of the 50 cyclization sequence
pseudoknot (DCS-PK), a three-stem pseudoknot structure located
in the capsid-coding region of mosquito-borne ﬂaviviruses (Liu
et al., 2013). Mutagenesis of an infectious clone of DENV-4 revealed
that disruption of the DCS-PK structure hindered the ability of 50
RNA to bind to 30 RNA, whereas restoration of the DCS-PK structure
facilitated recovery of the 50–30 complex demonstrating its role in
viral replication. Mutagenesis also showed that the function of
DCS-PK depends on its position relative to the 50 cyclization
sequence, its secondary structure and its speciﬁc primarysequence. Based on these results, the authors proposed that the
cis-acting element DCS-PK enhances viral replication by regulating
genome cyclization, and that DCS-PK might interact with other cis-
acting elements to form a functional viral RNA cyclization domain,
thus playing a critical role during the ﬂavivirus life cycle.4.2.5.3. Replication enhancer element. A unique replication enhancer
element (REE) was identiﬁed within the capsid gene of TBEV
(Tuplin et al., 2011). Using thermodynamic and phylogenetic anal-
yses, it was predicted that the REE folds as a long stable stem–loop
structure (designated SL6) with an exposed conserved hexanucleo-
tide among all tick-borne ﬂaviviruses (TBFV). To investigate the
role of SL6, a TBEV infectious clone was used to introduce nucleo-
tide substitutions which altered either the linear sequence of the
unpaired apical loop or destabilized the base-paired stem. The
greatest phenotypic changes were observed in mutants with a
destabilized stem while point mutations in the conserved hexanu-
cleotide motif of the terminal loop caused moderate virus attenu-
ation. However, the fact that all mutants eventually reached the
titer of wild-type virus late post-infection demonstrated that the
SL6 REE is not essential for growth in tissue culture but acts to
up-regulate virus replication.4.2.5.4. Cartography of the 30 UTR. The study of ﬂaviviral 30 UTR
sequences has attracted considerable interest and led to in depth
in silico analyses (Gritsun and Gould, 2007; Gritsun et al., 1997,
2006). Likewise, infectious clones have been used for mapping,
deﬁning and characterizing the various component parts of the
30 UTR. A series of progressive deletions was introduced into
the 30 UTR of a DENV-4 infectious clone and the viability of
the resulting mutants was analyzed (Men et al., 1996). Deletion
of the Conserved Sequence (CS) 1 in the 30-distal region, which is
highly conserved in the widely divergent MBFV group, com-
pletely abolished infectivity indicating that this sequence is
essential for virus replication. In contrast, deletion of either the
CS2-A or CS-2B or both (CS2), which are also conserved between
all MBFV, was not lethal.
Likewise, progressive upstream deletions from the CS2
towards the stop codon yielded viable mutant viruses although
they exhibited a spectrum of growth reduction in cell culture.
Thus, it was proposed that the boundary between viable and
lethal deletions lies immediately upstream of the CS1 as deletion
mutants that retain only the 30-distal regions CS1, SL2 and the
terminal long stable hairpin (30LSH) produced viable virus albeit
with low infectivity and only in mosquito cells. For infectivity in
vertebrate cells, the presence of CS2 was also essential. In gen-
eral, the impact of deletions in 30 UTRs downstream of CS1
was more profound in primate cell than in mosquito cells sug-
gesting that host factors may play an important role in efﬁcient
viral replication (Men et al., 1996).
Similar results were produced using an infectious clone of
YFV. The conserved sequence 50 CS and CS1 as well as the 30
stem loop structure were found to be essential for virus replica-
tion in cell culture whereas mutants with deletions in CS2 and
the region containing the YFV-speciﬁc repeated sequences
(between CS2 and the stop codon) still yielded viable viruses,
although with delayed growth properties and smaller plaque
size, suggesting that this region is not essential for virus viability
but may have a function related to virus replication efﬁciency
(Bredenbeek et al., 2003).
Deletions were also introduced in the 30 UTR of the TBEV (Mandl
et al., 1998) and the KUNV (Khromykh andWestaway, 1997). In sil-
ico analysis of the consequences of the introduction of deletions in
DENV, TBEV and KUNV was conducted to evaluate their impact on
secondary structures (Proutski et al., 1999).
Fig. 6. Schematic representation of the general approach for the design of YFV 17D-
based chimeric vaccine candidates. The sequences encoding the prM and E proteins
of the vaccine target virus (e.g., JEV, WNV, DENV or SLEV) were engineered into the
cDNA genome of the YFV 17D vaccine strain to replace the authentic prM and E
sequences. Chimeric viral RNA were obtained by in vitro transcription and were
transfected into permissive cells, resulting in the production of infectious chimeric
virus particles that are covered by the vaccine target virus envelope proteins.
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The development of reverse genetics methods made it possible
to develop new approaches to the production of live attenuated
vaccine candidates, (through the creation of chimeric viruses),
the discovery and characterization of potential antiviral therapeu-
tic molecules, and understanding the basis for the appearance of
drug resistance.
4.3.1. Chimeric vaccines
The ‘‘chimeric’’ approach for vaccine design is based on the
observation that structural genes of one ﬂavivirus can be
exchanged with equivalent genes from other related ﬂaviviruses
without signiﬁcantly affecting the replicative capacity of the
derived recombinant (chimeric) virus. For example the chimeric
virus could contain structural genes from one ﬂavivirus (e.g.,
prM and E protein) and the remaining parts of the genome
(including the terminal untranslated regions) from another ﬂavi-
virus to provide the ‘‘background’’ supporting genes which
encode non-structural proteins to provide replicative and protein
processing functions. The rationale behind this strategy is to
confer long-lasting protective immunity against pathogens using
a known attenuated virus to provide the backbone function for
the immunizing antigens. The E and prM proteins contain critical
antigenic determinants that induce protective neutralizing
antibodies.
The feasibility of this approach was ﬁrst demonstrated by Bray
and Lai (1991), who constructed the ﬁrst intertypic DENV chimeras
(Bray and Lai, 1991). The entire structural region (C-prM-E genes)
or only the envelope protein genes (prM-E) of a wild-type DENV-4
strain 814669, as well as the non-structural NS1 protein, weresuccessfully replaced with the corresponding genes from, DENV-
1, DENV-2 (Bray and Lai, 1991) (Bray et al., 1998), or DENV-3
(Chen et al., 1995). The chimeras grew in cell cultures, displayed
the expected antigenic speciﬁcities, and elicited protective levels
of expected neutralizing antibodies in monkeys (Bray et al., 1996).
These studies represent the foundation for the construction of a
variety of chimeric ﬂaviviruses that are being developed as poten-
tial live human vaccines. Due to its impressive safety record and
high efﬁcacy as a human vaccine, the attenuated YFV 17D strain
has been used as the backbone for the construction of some of
these chimeric vaccine viruses (see Fig. 6). First developed by
Chambers et al. (1999) and Monath et al. (1999) for the generation
of YFV/JEV chimera (Chambers et al., 1999; Monath et al., 1999),
YFV-based chimeric candidate vaccines have been subsequently
constructed for DENV (Caufour et al., 2001; Guirakhoo et al.,
2000, 2001, 2006; van Der Most et al., 2000), JEV (Monath et al.,
1999, 2003), WNV (Arroyo et al., 2004; Monath et al., 2001,
2006) and Saint Louis encephalitis virus (Pugachev et al., 2004)
and have now been extensively tested in clinical trials with results
that demonstrate their immunogenicity and good safety proﬁle
(Guy et al., 2008, 2010). Structural genes were either derived from
wild type (WT) viruses (e.g., DENV and veterinary WNV vaccine
candidates) or from empirically derived attenuated vaccines (e.g.,
JEV strain SA14-14-2) or by introduction of speciﬁc attenuating
mutations into the wild-type E gene by site directed mutagenesis
(e.g., NY99 strain for development of a human WNV vaccine).
The JEV strain SA14-14-2 has also been used as the backbone to
produce DENV-2/JEV, WNV/JEV or TBEV/JEV attenuated chimeras
(Li et al., 2013a,b; Wang et al., 2014). A chimeric WNV vaccine can-
didate, WNV/DENV-4, was also reported (Maximova et al., 2014;
Pletnev et al., 2002).
The issue of the possible occurrence of recombination between
a chimeric virus and a WT ﬂavivirus that could lead to the pro-
duction of a recombinant virus with unanticipated properties
has been raised and remains unanswered (Seligman and Gould,
2004).
4.3.2. Antiviral drugs
Infectious clones can be used to characterize antiviral drug
resistance mechanisms. For example, resistant mutants obtained
in cellulo by passaging the virus with increased concentrations of
antiviral drug, can be characterized using reverse genetics meth-
ods with infectious clones. By introducing the candidate muta-
tions into the genome of the infectious clone the resistance
phenotype of each mutated virus can be determined. This
approach was used to characterize the antiviral properties of
brequinar (BQR) using DENV (Qing et al., 2010). After appropri-
ate mutant selection in cell culture, followed by sequencing
and appropriate mutagenesis of the infectious clones, it was
demonstrated that a mutation in either the envelope or NS5
gene confers BQR resistance. Mechanistically, the envelope muta-
tion renders the mutant virus less susceptible to BQR inhibition
during the assembly/release phase whereas the NS5 mutation
confers resistance through enhancement of viral RNA synthesis.
In another study, Yang et al. (2014) used a stable reporter-
DENV replicon cell line to identify a small molecule inhibitor,
BP13944, which speciﬁcally inhibit all four serotypes of DENV.
Sequencing analyses of isolated resistant mutants identiﬁed a
consensus amino acid substitution (E66G) present within the
NS3 protease domain. Introduction of this mutation into a
DENV-2 infectious clone resulted in the apparition of the resis-
tance phenotype to BP13944. The location of the mutation,
within the interface between the protease and helicase domains
of the DENV NS3 protein, indicates that BP13944 may affect
DENV replication by binding to the protease interface (Yang
et al., 2014).
F. Aubry et al. / Antiviral Research 114 (2015) 67–85 815. Conclusions and perspectives
The availability of cDNA clones/PCR-amplicons has facilitated
the study of the genetic expression, replication and pathogenesis
of RNA viruses using mutagenesis, deletions, and insertions and
complementation experiments. It has also enhanced our under-
standing of the molecular mechanisms of natural or induced RNA
recombination as well as virus interactions with host cells and
organisms.
The production of infectious clones was an essential step in the
development of reverse genetics systems and is now beginning to
enable the acquisition of a huge amount of knowledge for these
viruses. Democratisation of the technology for de novo synthesis
and the huge developments, that have been made during recent
decades, have made it possible to generate new investigative
approaches that avoid the need to use critical steps for infectious
clone construction (cloning, propagation of cDNA into bacteria or
in vitro RNA transcription) thus providing easier, faster and more
reliable methods with which to unravel the scientiﬁc mysteries
discussed in this review. These methodologies will undoubtedly
continue to improve and become even more accessible, potentially
ensuring an increasingly exciting future for scientiﬁc investigation.
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